Rare Cancers: Clinical Trials
The question
To ask the Secretary of State for Health and Social Care, whether he plans to support early access to clinical trials for patients with rare cancers.
Answered by Ashley Dalton
The Department is committed to ensuring that all patients have access to cutting-edge clinical trials and innovative, life-saving treatments, including those with rare cancers.
We are also working to fast track clinical trials to drive global investment into life sciences, to improve health outcomes and to accelerate the development of medicines and therapies of the future, including for rare cancers.
The Department invests £1.6 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR). NIHR research expenditure for all cancers was £133 million across 2023/24, reflecting their high priority.
The forthcoming National Cancer Plan will include further details on how we will improve outcomes for cancer patients across the country, including patients with rare cancers. It will ensure that more patients have access to the latest treatments and technology, and to clinical trials.
The Government also supports the Rare Cancers Bill and its ambitions to incentivise clinical trials and access to innovative treatments for rare cancers.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →